Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
News|Articles|January 26, 2017
Celgene Adds New Fusion Protein to Portfolio with Delinia Acquisition
Author(s)Randi Hernandez
The company will gain the rights to a mutein that is believed to help maintain immune system homeostasis.
Advertisement
Celgene will further bolster its capabilities in immunology and autoimmune disorders with the acquisition of the biotechnology company Delinia, a move Celgene announced on Jan. 26, 2017. With the company comes the ownership of DEL106, a novel IL-2 mutein Fc fusion protein that is designed to upregulate regulatory T cells (Tregs).
Tregs maintain tolerance to self-antigens and are instrumental in the prevention of autoimmune diseases. Thus, Tregs are immunosuppressive and work to downregulate induction and proliferation of effector T cells. The cytokine IL-2 normally activates effector cells, but also drives expansion of Tregs to regulate the effector cells.
Celgene will pay Delinia an initial payment of $300 million, with additional payments of up to $475 million upon the development, regulatory, and commercial advances related to DEL106. DEL-106 is expected to start clinical trials in 2018.
Source:
Advertisement
Related to this article
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
Florin Muraru, Gourav Pandey, and Richard Jaenisch explain where human sign-off belongs as multi-agent AI and document-parsing models reach GxP.
In this episode of Ask the Expert, Siegfried Schmitt, PhD, vice president, Technical at Parexel, and Susan J. Schniepp, distinguished fellow at Nelson Labs, discuss how companies should approach post-approval changes to their CMC regulatory filings.
The EC has approved AstraZeneca's Trixeo Aerosphere as the first single-inhaler triple-combination therapy for asthma in the EU, based on phase e data showing improved lung function and fewer severe exacerbations in patients uncontrolled on standard ICS/LABA treatment.
In this episode of Pharma Fundamentals, Dr. Aleksandra Zuraw, senior veterinary pathologist at Charles River, provides an introduction to the use of digital pathology in drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
The FDA Finalizes Rule Recognizing Non-Animal Testing Methods, Building on Year-Long Reduction Push
2
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
3
PharmTech AI Pulse Check: Validating Multi-Agent Systems, OCR Models in GxP
4
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
5